Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineering high affinity superantigens by phage display.

Carolyn Enever1, Ian M Tomlinson, John Lund

  • 1MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK.

Journal of Molecular Biology
|March 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thermal imaging in the extended shortwave infrared band.

Applied optics·2026
Same author

Analysis and control of untemplated DNA polymerase activity for guided synthesis of kilobase-scale DNA sequences.

Nature communications·2026
Same author

A small polymerase ribozyme that can synthesize itself and its complementary strand.

Science (New York, N.Y.)·2026
Same author

Roles of dimeric intermediates in RNA-catalyzed rolling circle synthesis.

Nucleic acids research·2025
Same author

Trinucleotide substrates under pH-freeze-thaw cycles enable open-ended exponential RNA replication by a polymerase ribozyme.

Nature chemistry·2025
Same author

Cryo-EM structure and functional landscape of an RNA polymerase ribozyme.

Proceedings of the National Academy of Sciences of the United States of America·2024
Same journal

UPF3A and UPF3B shape the transcriptome cooperatively yet oppose cell function.

Journal of molecular biology·2026
Same journal

Antibody-secreting cells integrate efficient NMD with non‑canonical UPR signaling to maintain proteostasis and support massive immunoglobulin synthesis.

Journal of molecular biology·2026
Same journal

Small molecule stabilization of diverse amyloidogenic immunoglobulin light chains revealed by hydrogen-deuterium exchange mass spectrometry.

Journal of molecular biology·2026
Same journal

UPF1 at Work: Structural and Mechanistic Insights Into a Master Regulator of Nonsense-Mediated mRNA Decay.

Journal of molecular biology·2026
Same journal

Structural basis for the pro-amyloidogenic action and ligand binding of a novel W72R variant of human apolipoprotein A-I.

Journal of molecular biology·2026
Same journal

Cryo-EM Structure of the C. elegans Septin Tetramer Reveals a Revised Architecture and Conserved Positional Orthology.

Journal of molecular biology·2026
See all related articles

Engineered Protein L (PpL) variants show enhanced binding to human Vkappa light chains, improving diagnostic sensitivity and offering potential for immunotherapy applications.

Area of Science:

  • Immunology
  • Protein Engineering
  • Microbiology

Background:

  • Protein L (PpL) from Peptostreptococcus magnus is a B-cell superantigen that binds to mammalian Vkappa light chains.
  • The wild-type PpL contains five immunoglobulin (Ig) binding domains (B1-B5).

Purpose of the Study:

  • To engineer Protein L domains with improved affinity and specificity for human Vkappa light chains.
  • To evaluate the potential of engineered Protein L variants in immunochemistry and immunotherapy.

Main Methods:

  • Rational design and phage selection were used to create mutants of the N-terminal B1 domain.
  • Binding affinities of wild-type and mutant domains to human Vkappa subtypes were analyzed.
  • The utility of engineered domains as reagents in ELISA and in fusion proteins for immunotherapy was investigated.

Related Experiment Videos

Main Results:

  • Mutants B1kappa1 and B1kappa3 exhibited significantly increased affinity for human VkappaI and VkappaIII light chains, respectively.
  • The B1kappa1 domain demonstrated a tenfold increase in sensitivity for detecting human Vkappa antibody fragments in ELISA.
  • A fusion protein incorporating B1kappa1 facilitated antibody-mediated effector functions through retargeting of IgGkappa and IgMkappa.

Conclusions:

  • Protein engineering provides a straightforward method to enhance superantigen affinity and specificity.
  • Engineered Protein L domains show promise as valuable reagents in immunochemistry.
  • Engineered Protein L variants hold potential for development as immunotherapeutic agents.